-
Incyte To Stop A Phase 2 Sub-Study, Shares Lose 10%
Thursday, January 28, 2016 - 12:46pm | 152Shares of Incyte Corporation (NASDAQ: INCY) fell more than 10 percent on Thursday after the company said it will stop an ongoing Phase 2 sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP. According to Incyte's press release, the company...